Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Brand Name : AKP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2022
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Cannassure Therapeutics
Deal Size : $0.4 million
Deal Type : Expanded Collaboration
Details : Based on new IP (intellectual property), the scope of the collaboration agreement has expanded to include a new patent family covering innovative new AKVANO® topical formulations.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 29, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Cannassure Therapeutics
Deal Size : $0.4 million
Deal Type : Expanded Collaboration
Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Menarini
Deal Size : $83.1 million
Deal Type : Licensing Agreement
Details : Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.
Brand Name : AKP01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Menarini
Deal Size : $83.1 million
Deal Type : Licensing Agreement
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO® technology.
Brand Name : AKP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2021
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Cannassure Therapeutics
Deal Size : $0.4 million
Deal Type : Collaboration
Details : Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Cannassure Therapeutics
Deal Size : $0.4 million
Deal Type : Collaboration
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Cadila Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate
Details : Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spr...
Brand Name : AKP-02
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 07, 2020
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Cadila Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House
Details : Company has successfully completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and is planning for a licensing project.
Brand Name : AKP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 07, 2020
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Both Lipidor's AKP01 and the comparator had a statistically significantly better efficacy compared to the placebo.
Brand Name : AKP01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2020
Lead Product(s) : Calcipotriol
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?